AI Summary
Danaher reported solid Q2 2026 results with revenue up 5.5% to $6.3B and net earnings of $870M ($1.23 per share). Non-GAAP core revenue rose 3.0% (4.5% excluding respiratory testing), and operating cash flow reached $1.5B with $1.3B in free cash flow. The earlier-than-expected Masimo acquisition completion supports an elevated 2026 EPS guidance of $8.45–$8.60 and mid-single-digit core revenue growth for the year.
Sentiment Rationale
Strong Q2 beat, EPS upgrade, and Masimo integration create a clearer path to higher annual earnings and cash flow, supporting multiple expansion versus prior levels. History shows Danaher’s results-driven stock tends to respond positively to earnings upgrades and meaningful M&A-driven synergies, though execution risk and integration costs remain headwinds.
Trading Thesis
Bullish on DHR over the next 6–12 months as Masimo integration lifts earnings and cash flow.
Market-Moving
- Masimo acquisition closed earlier-than-expected, enabling higher 2026 guidance.
- 2026 non-GAAP core revenue growth guided at 3–4% with higher EPS target.
- New non-GAAP core revenue metric excludes respiratory testing; may affect comparability.
- StatLab/Leica-related growth potential remains a near-term catalyst.
Key Facts
- Revenue $6.3B, up 5.5% YoY; net earnings $870M, EPS $1.23.
- Non-GAAP core revenue up 3.0%; excluding respiratory testing, +4.5%.
- Masimo acquisition completed earlier-than-expected; raises 2026 EPS guidance.
- Operating cash flow $1.5B; non-GAAP free cash flow $1.3B.
- Guidance raised: 2026 core revenue +3–4%; adjusted EPS $8.45–$8.60.
Companies Mentioned
- Danaher Corporation (DHR): Reported Q2 2026 results; raised full-year guidance, underscoring earnings leverage from the Danaher Business System.
- Masimo Corporation (MASI): Acquisition closed earlier than anticipated; drove up guidance and potential synergy across Life Sciences and Diagnostics.
Earnings
Category: Earnings. The release centers on Q2 results, guidance upgrades, and the Masimo acquisition, which together redefine Danaher's near-term earnings trajectory and cash-flow profile.